Miller Howard Investments Inc. NY increased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 23.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 517,996 shares of the company's stock after buying an additional 99,040 shares during the quarter. Johnson & Johnson accounts for approximately 2.7% of Miller Howard Investments Inc. NY's investment portfolio, making the stock its 4th largest position. Miller Howard Investments Inc. NY's holdings in Johnson & Johnson were worth $85,904,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. WealthTrak Capital Management LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson during the 4th quarter valued at approximately $29,000. Conquis Financial LLC acquired a new stake in Johnson & Johnson during the 4th quarter valued at approximately $33,000. Bernard Wealth Management Corp. acquired a new stake in Johnson & Johnson during the 4th quarter valued at approximately $36,000. Finally, Highline Wealth Partners LLC increased its position in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.
Johnson & Johnson Stock Up 0.2%
Shares of JNJ traded up $0.34 during trading hours on Friday, reaching $155.90. The stock had a trading volume of 3,482,521 shares, compared to its average volume of 8,059,757. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The firm has a 50-day simple moving average of $153.68 and a 200 day simple moving average of $154.09. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $375.11 billion, a price-to-earnings ratio of 17.34, a P/E/G ratio of 2.36 and a beta of 0.41.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The company had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were issued a $1.30 dividend. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.34%. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.
Wall Street Analyst Weigh In
A number of analysts have weighed in on JNJ shares. Barclays decreased their target price on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Royal Bank Of Canada reissued an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 5th. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their target price for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Wall Street Zen raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Finally, Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Eleven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average target price of $170.88.
Check Out Our Latest Analysis on JNJ
Johnson & Johnson Company Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
